T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
CareCloud
CCLD
$104M
| $28K | ﹤0.01% |
23,700
-9,500
| -29% | -$20K |
|
2827
Phunware
PHUN
$43M
| $28K | ﹤0.01% |
3,094
+1,522
| +97% | +$25.2K |
|
2828
Altimmune
ALT
$570M
| $27K | ﹤0.01% |
10,047
-15,600
| -61% | -$44.8K |
|
2829
Protalix BioTherapeutics
PLX
$211M
| $27K | ﹤0.01% |
15,982
+4,535
| +40% | +$8.14K |
|
2830
Cartesian Therapeutics
RNAC
$263M
| $26K | ﹤0.01% |
789
-727
| -48% | -$24.3K |
|
2831
Neuronetics
STIM
$223M
| $26K | ﹤0.01% |
19,100
| – | – |
|
|
GTHX
2832
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $26K | ﹤0.01% |
17,755
| – | – |
|
2833
Lufax Holding
LU
$1.33B
| $25K | ﹤0.01% |
5,700
| – | – |
|
|
SLGCW
2834
DELISTED
SomaLogic, Inc. Warrant
SLGCW
| $25K | ﹤0.01% |
110,347
-1,353
| -1% | -$332 |
|
|
EQRXW
2835
DELISTED
EQRx, Inc. Warrant
EQRXW
| $25K | ﹤0.01% |
608,474
-2,986
| -0.5% | -$308 |
|
|
CAMP
2836
DELISTED
CalAmp Corp.
CAMP
| $24K | ﹤0.01% |
2,565
+1,456
| +131% | +$24.4K |
|
2837
Smartbird Inc
BIRD
$30.2M
| $23K | ﹤0.01% |
1,030
+164
| +19% | +$4.42K |
|
2838
Lightpath Technologies
LPTH
$862M
| $23K | ﹤0.01% |
15,300
| – | – |
|
|
FUV
2839
DELISTED
Arcimoto, Inc. Common Stock
FUV
| $23K | ﹤0.01% |
26,725
| – | – |
|
2840
Heron Therapeutics
HRTX
$64.7M
| $22K | ﹤0.01% |
20,804
-35,800
| -63% | -$51K |
|
|
XXII
2841
22nd Century Group
XXII
$1.49M
| – | – |
0
| – | – |
|
2842
Bakkt Inc
BKKT
$336M
| $20K | ﹤0.01% |
655
+246
| +60% | +$8.71K |
|
|
OPTN
2843
DELISTED
OptiNose
OPTN
| $19K | ﹤0.01% |
993
-13,871
| -93% | -$250K |
|
2844
Veru
VERU
$46.7M
| $19K | ﹤0.01% |
2,530
| – | – |
|
2845
Citius Pharmaceuticals
CTXR
$21M
| $18K | ﹤0.01% |
1,000
-940
| -48% | -$22.3K |
|
2846
System1
SST
$19.8M
| $18K | ﹤0.01% |
1,435
| – | – |
|
2847
INNOVATE Corp
VATE
$105M
| $18K | ﹤0.01% |
+1,053
| New | +$17.6K |
|
2848
VirnetX Holding Corp
VHC
$65.8M
| $18K | ﹤0.01% |
3,450
| – | – |
|
|
TVRD
2849
Tvardi Therapeutics
TVRD
$22.1M
| $18K | ﹤0.01% |
+290
| New | +$27.2K |
|
|
RAD
2850
DELISTED
Rite Aid Corporation
RAD
| $18K | ﹤0.01% |
38,580
+19,200
| +99% | +$25.7K |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.